The $10‚000 investment made into Johnson and Johnson is a good investment to have in your portfolio. This is because of the stable nature of Johnson and Johnson and the growth trend of the company. Based on the JNJ 10-Ks for the last 5 years ended Jan. 1‚ 2012‚ the revenue trend is growing. Revenues have trended favorably from $61‚095 in the year ended Jan. 2007 to $65‚030 in the year ended Jan. 1‚ 2012. The company is also operating efficiently showing the more stable aspect of this investment
Premium Investment Asset Financial ratios
1.What factors help to explain why J&J historically had as many as 12 distribution centers in Europe? By placing so many centers in Europe‚ Johnson & Johnson were focused on meeting the specific needs and service expectations of their customers. By having multiple centers strategically located throughout the country‚ the transportation costs remained low and they could meet certain needs of customers‚ like one day shipping‚ 2 day shipping‚ etc. 2.What steps in the logistics/supply chain network
Premium Supply chain management Logistics Supply chain
MG 496 Case #2 Johnson & Johnson (Case #21) External Factors Analysis • Economic I. Economic crisis directly affected R&D budget (2009) threat II. Currency rate fluctuations III. Change in consumer behaviors and spending patterns of health care products and services due to economic downfall. threat • Political/ Legal I. Government legislation relating to sales‚ promotions‚ and reimbursement II. Patent expirations (Patent Cliffs); could decrease demand for a
Premium Food and Drug Administration Pharmacology Advertising
Technique analysis Firstly‚ Johnson & Johnson Pharmaceutical uses focused differentiation technique in marketing its new proprietary medicines (Saylor 5‚ 2013). In 2013‚ it came up with three major medicines: INVOKANA (canagliflozin)‚ IMBRUVICA (ibrutinib) and OLYSIO (simeprevir) (Johnson & Johnson [J&J]‚ 2013). Each medicine has its own focused market: INVOKANA for Type 2 diabetic patients‚ which affects approximately 26 million people in the United States; IMBRUVICA for people with the rare mantle
Premium Blood sugar Blood sugar Health care
The decision of Johnson & Johnson Acquires Dabao. Di Wang MGT 540 MI004 Professor: Arthur Annechino 20th February 2013 Table of Contents Executive Summary 3 Introduction 4 The reasons of decision 6 Decision making style 7 The problem in decision making process 8 Recommendations 9 Conclusion 11 Reference 12 Executive Summary This paper is talking about the Johnson & Johnson Acquires Dabao. It starts with review the two companies’ history‚ and then shows the
Premium Cosmetics Decision making
Running head: JOHNSON & JOHNSON – FROM BAND-AIDS TO SAVING LIVES Johnson & Johnson: A Global Approach to Health Care Your Name Here Webster University Abstract Johnson & Johnson is a world leader in health care products and services. In this paper‚ I thoroughly analyze the foundation of Johnson & Johnson to determine the characteristics that make the corporation successful. My paper explains the organizational structure within the company and identifies a few members on the board of directors
Premium Johnson & Johnson Health care
The Johnson & Johnson Tylenol Incident In 1982 Johnson and Johnson‚ the pharmaceutical company that makes Tylenol announced a nationwide recall of Tylenol; 31 million bottles and a loss of 100 million dollars. This recall was secondary to the death of seven people in the Chicago area after using Tylenol. An investigation reveled the poisoning were found to be that of an outside source. The Tylenol was contaminated with cyanide from an outside source. Johnson and Johnson ’s response to the poisonings
Premium Tylenol Johnson & Johnson Pharmacology
Paper 1 EXTERAL ANALYSIS Macroenvironmental Analysis: • Economic: Globalization of the pharmaceutical industry is an exciting opportunity to have research and development done at cheaper prices in other countries. However‚ this could be a double edged sword for companies because it is easy for other countries‚ such as India‚ to produce generic versions of the drug in bulk. • Technological: Profitability is determined mainly by the ability to discover new drugs. Technology is at the forefront
Premium Johnson & Johnson
Johnson & Johnson: Successfully Strategizing for the Changing Global Business Environment I. Introduction Johnson & Johnson is the world’s largest healthcare company. Founded in the United States in 1886‚ the company has been profitable for 75 straight years and currently operates 250 subsidiary companies in 57 countries. Its products fall into three segments: pharmaceuticals‚ with 39% of total sales; medical devices and diagnostics‚ with 36%;
Premium Generic drug Pharmaceutical industry Medicine
BUSINESS DECISION MAKING INTRODUCTION Johnson and Johnson is an American multinational company founded in Brunswick ‚New Jersey in 1886 by American entrepreneur Robert Wood Johnson. It manufactures pharmaceuticals‚ medical devices and consumer products. J&J and its subsidiaries have operations in over 60 countries and sell their products in over 175 countries. Today‚ it employs 120‚000 people worldwide. They are the world’s second largest manufacturer of health care products and
Premium Johnson & Johnson Pharmaceutical industry SWOT analysis